View Post

Myeloma Drug Gets All Thumbs Up From FDA Panel

In Clinical Studies News by Barbara Jacoby

By: Charles Bankhead From: medpagetoday.com An FDA advisory committee voted unanimously to recommend approval of the antibody-drug conjugate (ADC) belantamab mafodotin for last-line treatment of relapsed/refractory multiple myeloma (RRMM). In voting 12-0 in favor of approval, the Oncologic Drugs Advisory Committee (ODAC) found that belantamab mafodotin’s efficacy clearly outweighed the risk of a novel ocular toxicity not seen with other …